<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Left atrial (LA) <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was sometimes found by transesophageal echocardiography (TEE) in non-valvular <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF), even in the setting of continuous <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>A D-dimer cutoff level of 0.50 μg/mL appears to be a useful marker to rule out venous vein <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>This study analyzed the clinical features of patients with LA <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> who received <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy and whether the D-dimer test is useful to exclude LA <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Two hundred twenty-five consecutive patients with AF (149 with paroxysmal and 76 with persistent) were enrolled </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received continuous <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy with the prothrombin time-international normalized ratio (PT-INR) between 1.6 and 3.0 for more than 3 months and TEE was performed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: LA <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were present in 23 and absent in 202 patients </plain></SENT>
<SENT sid="6" pm="."><plain>Age, gender, and PT-INR (1.96 ± 0.59 vs. 1.98 ± 0.53) were not different between the two groups </plain></SENT>
<SENT sid="7" pm="."><plain>Persistent AF (65 vs. 30%; p &lt; 0.005), LA diameter (44 ± 5 vs. 40 ± 7 mm; p &lt; 0.005), ejection fraction (57 ± 13 vs. 65 ± 9%; p &lt; 0.005), brain natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> levels (203 ± 209 vs. 105 ± 166 pg/mL; p &lt; 0.05), D-dimer (0.55 ± 0.70 vs. 0.16 ± 0.20 μg/mL; p &lt; 0.001), LA appendage flow velocity (33 ± 15 vs. 54 ± 19 cm/s; p &lt; 0.001), CHADS(2) scores (2 ± 1 vs. 1 ± 1; p &lt; 0.005), and CHA(2)DS(2)-VASc scores (3 ± 2 vs. 2���± 1; p &lt; 0.005) were significantly different in both groups </plain></SENT>
<SENT sid="8" pm="."><plain>Although multivariate analysis showed that D-dimer and LA appendage flow velocity were significant independent predictors of LA <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e>, D-dimer levels below 0.5 μg/mL were found in 19 of 23 patients with LA <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: D-dimer levels below 0.5 μg/mL is not enough to rule out LA <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> in AF patients with well-controlled anticoagulation </plain></SENT>
</text></document>